In addition to PSMA and GRPR, numerous alternative molecular targets have been explored for PCa imaging and therapy using 64Cu-labeled radiopharmaceuticals, each offering unique biological rationales and translational potential (Tables 6 and 7). The gene discussed is GRPR; the disease is posterior cortical atrophy.